Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
about
Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment optionsCeftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infectionsBeyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing CarbapenemasesAdvances in antibiotic therapy in the critically illPseudomonas aeruginosa ventilator-associated pneumonia managementThe β-Lactams Strike Back: Ceftazidime-AvibactamHealthcare-associated infections, infection control and the potential of new antibiotics in development in the USACeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsWhat's new in multidrug-resistant pathogens in the ICU?Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsInvestigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibitionEmergence and dissemination of multi-resistant Gram negative Enterobacteriaceae: lessons to be learnt from local and national surveillance programs in Belgium.New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignanciesRole of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjectsβ-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates.Pipeline of Known Chemical Classes of Antibiotics.Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsTreatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Carbapenem-Resistant Enterobacteriaceae Infections in Children.Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistanceSecretome Prediction of Two M. tuberculosis Clinical Isolates Reveals Their High Antigenic Density and Potential Drug Targets.Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.The intrinsic resistome of bacterial pathogens.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.β-lactam/β-lactamase inhibitor combinations: from then to now.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
P2860
Q21146707-358C6A87-F2BC-47DB-B8FF-37BF32AF2E57Q26741312-C5D9F825-1D58-4EDC-A55E-00070A06423BQ26747580-DEC13943-2E41-471B-973C-6AAB504EE585Q26749328-14990C31-7EE4-4D6E-8496-6050997EDC6EQ26768365-675B5CEC-88B6-4FAB-A2C2-9EF90DB7EDF3Q26796425-A686EE39-04A7-4805-8E55-85D2385701BEQ26995305-794A80B1-53F7-425B-8244-84F2B7D96D95Q28069563-D4096FD2-33B0-4278-AA3D-9B218E346859Q28071346-28C83CE3-FB43-4580-B0A5-038D383892C0Q28082546-39AA1A34-3E4A-4761-8802-C97F9FAB9E28Q28834096-CE973EDB-23F7-45DF-B3EF-2C94A2DB9A0CQ30368402-6A3A8BCA-B342-42C9-BF1C-53127455A8EEQ33622976-23F38BE5-DB78-46E4-9F38-0744DE6BDFD9Q33686940-1376E85C-0E52-4216-ADB3-831E01B43AE7Q33816251-5FE57840-5676-474D-A2C7-6591B062EAEEQ34057425-AB5CACC9-AC2F-46D7-BC08-73F4C027756EQ34402134-552C9ABB-08D5-4E71-B908-F227FCB41BD3Q34596516-427524A1-51BD-4A9F-BB64-8A7A6E4AB40EQ35545954-76DBEA6D-E89A-4594-811E-A9CD86D2980EQ35960745-BE21CF01-B044-4EB7-91D9-4DE03E2ECC5AQ36075788-FF70314A-09D2-4D7F-AA94-D9CF3FC571A4Q36201543-3D2AF531-8859-4F28-A02F-1458203B4E9AQ36644786-F74ADF1C-ADF9-4735-94BF-1EE3D7CADDDCQ36683409-6F11FD80-AE9F-44BD-A47F-1731265F4A09Q36683532-3AD8C8C9-8E20-46FF-A9C5-A30F1E1EF854Q36761826-14010757-9487-4801-8206-A51EF3DD1FA2Q36915096-A011B327-FDD1-4B98-AC0A-9AE75E8D8CA9Q37055016-9C122940-71D9-4120-BC7A-3481875AA7DFQ37146405-BA760E61-CC37-40AF-BE70-04AF450A7BA3Q37154718-71D93D2A-0785-4CB2-8301-1A5E9A952C4EQ37287753-1476CA9F-2051-4414-9272-ECF273981CB8Q37411475-965FC9AE-C4E5-41E3-8A95-AEDEC83D7EB6Q37627084-7E509D2A-FABA-43B6-9C79-BF604909583FQ37643614-BA73697A-DBFA-4CA4-A26B-38E012CBB6ECQ38103861-2EB7AB69-499D-4B01-91E7-4216267213DBQ38130715-F8413526-6174-40CD-8B15-B92ED7A010A0Q38232197-A811C1AF-DC42-4C86-B7E5-5CFBC629B8C6Q38264182-BB8EAC84-22C9-43E2-BB58-FCE286118795Q38286351-324CD5A8-DDA7-4574-9B32-EB2E73DC05F2Q38543002-03026960-0105-4241-B728-A12D8D7852A0
P2860
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Comparative study of the effic ...... double-blind, Phase II trial.
@en
Comparative study of the effic ...... double-blind, Phase II trial.
@nl
type
label
Comparative study of the effic ...... double-blind, Phase II trial.
@en
Comparative study of the effic ...... double-blind, Phase II trial.
@nl
prefLabel
Comparative study of the effic ...... double-blind, Phase II trial.
@en
Comparative study of the effic ...... double-blind, Phase II trial.
@nl
P2093
P2860
P356
P1476
Comparative study of the effic ...... double-blind, Phase II trial.
@en
P2093
Carole Sable
Christopher Lucasti
Irinel Popescu
Mayakonda K Ramesh
P2860
P304
P356
10.1093/JAC/DKS523
P407
P577
2013-02-07T00:00:00Z